TY - JOUR T1 - Renin-angiotensin system inhibitors in COVID-19 JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med DO - 10.3949/ccjm.87a.ccc009 AU - George Thomas Y1 - 2020/05/14 UR - http://www.ccjm.org/content/early/2020/05/12/ccjm.87a.ccc009.abstract N2 - Concerns have been raised about the potential for renin-angiotensin system (RAS) inhibitors to upregulate expression of angiotensin-converting enzyme 2 (ACE2) and thus increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, there is no evidence that even if RAS inhibitors increase expression and activity of ACE2, that they would increase the risk of SARS-CoV-2 infection by facilitating greater viral entry or worsen outcomes in patients with COVID-19. At this time, there is no clinical evidence to suggest that treatment with RAS inhibitors should be discontinued in stable patients with COVID-19. In hospitalized patients with severe COVID-19, decisions about these medications should be based on clinical condition, including hemodynamic status and renal function. ER -